阿尔茨海默-话题@MedSci

#阿尔茨海默#

756篇内容 | 7925人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1470345, encodeId=7d3d14e034577, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=INmune Bio宣布临床前数据，证明其sTNF抑制剂降低肥胖者患阿尔茨海默氏病的潜力, objectType=article, longId=185656, objectId=25ab1856567d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ab1856567d, replyNumber=0, likeNumber=16, createdTime=2020-01-05, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ab1856567d, moduleTitle=INmune Bio宣布临床前数据，证明其sTNF抑制剂降低肥胖者患阿尔茨海默氏病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ab1856567d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470344, encodeId=fe6914e034439, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=CLIN CHEM LAB MED：脑脊液液体活检确认神经元五种毒素受体（NPTXR）作为阿尔茨海默氏病进展的生物标志物？, objectType=article, longId=185596, objectId=b3ea18559605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3ea18559605, replyNumber=0, likeNumber=73, createdTime=2020-01-04, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3ea18559605, moduleTitle=CLIN CHEM LAB MED：脑脊液液体活检确认神经元五种毒素受体（NPTXR）作为阿尔茨海默氏病进展的生物标志物？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3ea18559605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470343, encodeId=bd3914e03432d, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=Biogen以4500万美元收购Ionis早期阿尔茨海默氏症药物--靶向tau蛋白, objectType=article, longId=185043, objectId=660818504339, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=660818504339, replyNumber=0, likeNumber=78, createdTime=2019-12-23, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=660818504339, moduleTitle=Biogen以4500万美元收购Ionis早期阿尔茨海默氏症药物--靶向tau蛋白, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=660818504339)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470342, encodeId=087e14e03424a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=Sci Transl Med：阿尔茨海默症浮现新的诊断指标！, objectType=article, longId=184590, objectId=92e91845907a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92e91845907a, replyNumber=0, likeNumber=55, createdTime=2019-12-13, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92e91845907a, moduleTitle=Sci Transl Med：阿尔茨海默症浮现新的诊断指标！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92e91845907a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470341, encodeId=9f0b14e0341e5, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=起死回生”的阿尔茨海默病新药的详细数据该怎么理解？, objectType=article, longId=184323, objectId=1583184323d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1583184323d3, replyNumber=0, likeNumber=60, createdTime=2019-12-08, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1583184323d3, moduleTitle=起死回生”的阿尔茨海默病新药的详细数据该怎么理解？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1583184323d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470340, encodeId=04c714e03400f, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=初步调查排除了中国阿尔茨海默氏症药物开发者的学术造假行为, objectType=article, longId=184027, objectId=968518402e4c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=968518402e4c, replyNumber=0, likeNumber=48, createdTime=2019-12-04, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=968518402e4c, moduleTitle=初步调查排除了中国阿尔茨海默氏症药物开发者的学术造假行为, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=968518402e4c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470339, encodeId=b91014e033937, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=JCEM：二甲双胍与糖尿病患者阿尔茨海默氏病风险的关系, objectType=article, longId=183797, objectId=6d97183e978e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d97183e978e, replyNumber=0, likeNumber=68, createdTime=2019-12-01, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d97183e978e, moduleTitle=JCEM：二甲双胍与糖尿病患者阿尔茨海默氏病风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d97183e978e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470338, encodeId=1b5a14e0338b9, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=Nature：又一力证，炎症驱动阿尔茨海默症, objectType=article, longId=183681, objectId=415e183681ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415e183681ee, replyNumber=0, likeNumber=72, createdTime=2019-11-28, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415e183681ee, moduleTitle=Nature：又一力证，炎症驱动阿尔茨海默症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415e183681ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470337, encodeId=462714e03372d, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=FDA批准：间充质干细胞治疗阿尔茨海默症的突破性临床试验, objectType=article, longId=183350, objectId=73a4183350de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73a4183350de, replyNumber=0, likeNumber=59, createdTime=2019-11-23, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73a4183350de, moduleTitle=FDA批准：间充质干细胞治疗阿尔茨海默症的突破性临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73a4183350de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470336, encodeId=83db14e03360e, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=国产阿尔茨海默症药物发明人，被曝涉嫌多篇学术论文造假, objectType=article, longId=182580, objectId=d43818258065, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d43818258065, replyNumber=0, likeNumber=14, createdTime=2019-11-09, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d43818258065, moduleTitle=国产阿尔茨海默症药物发明人，被曝涉嫌多篇学术论文造假, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d43818258065)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470335, encodeId=e09714e03352c, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=**学术期刊连发两文，需谨慎对待中国批准的治疗阿尔茨海默新药, objectType=article, longId=182578, objectId=92aa1825e838, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92aa1825e838, replyNumber=0, likeNumber=104, createdTime=2019-11-09, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92aa1825e838, moduleTitle=**学术期刊连发两文，需谨慎对待中国批准的治疗阿尔茨海默新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92aa1825e838)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470334, encodeId=fe9d14e0334d3, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=Science：国际学界热议中国阿尔茨海默症新药, objectType=article, longId=182554, objectId=c7db182554e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7db182554e9, replyNumber=0, likeNumber=56, createdTime=2019-11-09, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7db182554e9, moduleTitle=Science：国际学界热议中国阿尔茨海默症新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7db182554e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470333, encodeId=46f014e033399, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=分析师表示，FDA对Biogen的阿尔茨海默症药物的裁决可能是"政治决定", objectType=article, longId=182456, objectId=10d018245665, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10d018245665, replyNumber=0, likeNumber=95, createdTime=2019-11-07, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10d018245665, moduleTitle=分析师表示，FDA对Biogen的阿尔茨海默症药物的裁决可能是"政治决定", moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10d018245665)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470332, encodeId=734d14e0332f5, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=中国监管机构有条件批准绿谷药业甘露寡糖二酸治疗轻度至中度阿尔茨海默病, objectType=article, longId=182362, objectId=f1f4182362f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1f4182362f6, replyNumber=0, likeNumber=101, createdTime=2019-11-06, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1f4182362f6, moduleTitle=中国监管机构有条件批准绿谷药业甘露寡糖二酸治疗轻度至中度阿尔茨海默病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1f4182362f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470331, encodeId=22d514e0331b1, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=中国阿尔茨海默病新药GV-791引发巨大争议，理性对待为宜, objectType=article, longId=182356, objectId=67e21823561d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e21823561d, replyNumber=0, likeNumber=59, createdTime=2019-11-05, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e21823561d, moduleTitle=中国阿尔茨海默病新药GV-791引发巨大争议，理性对待为宜, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e21823561d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470330, encodeId=999114e03308c, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=药品上市许可人制度助力阿尔茨海默病创新药获批, objectType=article, longId=182334, objectId=a46f182334ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a46f182334ba, replyNumber=0, likeNumber=89, createdTime=2019-11-05, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a46f182334ba, moduleTitle=药品上市许可人制度助力阿尔茨海默病创新药获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a46f182334ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470329, encodeId=e0fb14e03294b, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=创新药“九期一”有条件批准上市！用于轻至中度阿尔茨海默病, objectType=article, longId=182295, objectId=1b7b1822954e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b7b1822954e, replyNumber=0, likeNumber=73, createdTime=2019-11-04, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b7b1822954e, moduleTitle=创新药“九期一”有条件批准上市！用于轻至中度阿尔茨海默病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b7b1822954e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470328, encodeId=15b514e0328d8, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=ARCH PATHOL LAB MED：阿尔茨海默病II型星形胶质细胞在肝性脑病中的敏感性和特异性, objectType=article, longId=181883, objectId=66e2181883cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66e2181883cc, replyNumber=0, likeNumber=71, createdTime=2019-10-26, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66e2181883cc, moduleTitle=ARCH PATHOL LAB MED：阿尔茨海默病II型星形胶质细胞在肝性脑病中的敏感性和特异性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66e2181883cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470327, encodeId=b61714e0327fb, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, objectType=article, longId=181870, objectId=66f71818e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66f71818e0a7, replyNumber=0, likeNumber=91, createdTime=2019-10-26, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66f71818e0a7, moduleTitle=Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66f71818e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1470326, encodeId=d1ed14e032612, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, objectTitle=Biogen将向FDA申请阿尔茨海默症治疗药物Aducanumab的监管备案, objectType=article, longId=181799, objectId=6cee181e9981, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6cee181e9981, replyNumber=0, likeNumber=62, createdTime=2019-10-24, rootId=0, userName=yhj-time, userId=c5917090900, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6cee181e9981, moduleTitle=Biogen将向FDA申请阿尔茨海默症治疗药物Aducanumab的监管备案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6cee181e9981)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阿尔茨海默

2020-05-29

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

INmune Bio宣布临床前数据，证明其sTNF抑制剂降低肥胖者患阿尔茨海默氏病的潜力

2020-01-05

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

CLIN CHEM LAB MED：脑脊液液体活检确认神经元五种毒素受体（NPTXR）作为阿尔茨海默氏病进展的生物标志物？

2020-01-04

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

Biogen以4500万美元收购Ionis早期阿尔茨海默氏症药物--靶向tau蛋白

2019-12-23

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

Sci Transl Med：阿尔茨海默症浮现新的诊断指标！

2019-12-13

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

起死回生”的阿尔茨海默病新药的详细数据该怎么理解？

2019-12-08

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

初步调查排除了中国阿尔茨海默氏症药物开发者的学术造假行为

2019-12-04

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

JCEM：二甲双胍与糖尿病患者阿尔茨海默氏病风险的关系

2019-12-01

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

Nature：又一力证，炎症驱动阿尔茨海默症

2019-11-28

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

FDA批准：间充质干细胞治疗阿尔茨海默症的突破性临床试验

2019-11-23

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

国产阿尔茨海默症药物发明人，被曝涉嫌多篇学术论文造假

2019-11-09

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

**学术期刊连发两文，需谨慎对待中国批准的治疗阿尔茨海默新药

2019-11-09

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

Science：国际学界热议中国阿尔茨海默症新药

2019-11-09

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

分析师表示，FDA对Biogen的阿尔茨海默症药物的裁决可能是"政治决定"

2019-11-07

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

中国监管机构有条件批准绿谷药业甘露寡糖二酸治疗轻度至中度阿尔茨海默病

2019-11-06

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

中国阿尔茨海默病新药GV-791引发巨大争议，理性对待为宜

2019-11-05

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

药品上市许可人制度助力阿尔茨海默病创新药获批

2019-11-05

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

创新药“九期一”有条件批准上市！用于轻至中度阿尔茨海默病

2019-11-04

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

ARCH PATHOL LAB MED：阿尔茨海默病II型星形胶质细胞在肝性脑病中的敏感性和特异性

2019-10-26

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

Biogen的aducanumab治疗阿尔茨海默氏病符合III期试验终点

2019-10-26

yhj-time (审核中...)

前往app查看评论内容

#阿尔茨海默#

Biogen将向FDA申请阿尔茨海默症治疗药物Aducanumab的监管备案

2019-10-24

科室
- - 订阅+
  - 更多科室
工具
服务